SAN DIEGO – Gazyva (obinutuzumab), the drug considered a follow-on to blockbuster Rituxan (rituximab) – as well as a buffer to impending biosimilar versions of rituximab – improved progression-free survival (PFS) by 34 percent compared to Rituxan in patients with previously untreated follicular lymphoma (FL), according to detailed data presented at the American Society of Hematology (ASH) meeting, though the side-effect profile could give some physicians pause, as could the lack of an overall survival benefit.